- Home
- MPV vs MGNX Comparison
MPV vs MGNX Comparison
Compare MPV & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPV
- MGNX
- Stock Information
- Founded
- MPV 1988
- MGNX 2000
- Country
- MPV United States
- MGNX United States
- Employees
- MPV N/A
- MGNX N/A
- Industry
- MPV Finance Companies
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MPV Finance
- MGNX Health Care
- Exchange
- MPV Nasdaq
- MGNX Nasdaq
- Market Cap
- MPV 181.3M
- MGNX 202.7M
- IPO Year
- MPV N/A
- MGNX 2013
- Fundamental
- Price
- MPV $16.90
- MGNX $2.76
- Analyst Decision
- MPV
- MGNX Hold
- Analyst Count
- MPV 0
- MGNX 10
- Target Price
- MPV N/A
- MGNX $7.17
- AVG Volume (30 Days)
- MPV 25.2K
- MGNX 768.5K
- Earning Date
- MPV 01-01-0001
- MGNX 03-06-2025
- Dividend Yield
- MPV 8.71%
- MGNX N/A
- EPS Growth
- MPV N/A
- MGNX N/A
- EPS
- MPV 1.71
- MGNX N/A
- Revenue
- MPV N/A
- MGNX $141,329,000.00
- Revenue This Year
- MPV N/A
- MGNX $174.73
- Revenue Next Year
- MPV N/A
- MGNX N/A
- P/E Ratio
- MPV $9.35
- MGNX N/A
- Revenue Growth
- MPV N/A
- MGNX 16.68
- 52 Week Low
- MPV $11.18
- MGNX $2.34
- 52 Week High
- MPV $16.42
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- MPV 48.99
- MGNX 45.32
- Support Level
- MPV $17.03
- MGNX $2.34
- Resistance Level
- MPV $17.77
- MGNX $2.95
- Average True Range (ATR)
- MPV 0.40
- MGNX 0.17
- MACD
- MPV 0.05
- MGNX 0.03
- Stochastic Oscillator
- MPV 50.85
- MGNX 61.76
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).